Autor(es): Mulhearn Ben; Bruce Ian N.

Resumo: The use of IVIG to treat a wide variety of immune-driven diseases has grown rapidly, although the mechanism of action is not completely understood. Increasing demand for IVIG coupled with concerns regarding potential transmissible agents has led to worldwide suply shortages. National agencies have therefore produced guidelines for its use, with the latest England and Wales guideline being published in 2011. Due to the rarity of the rheumatic diseases, the evidence for IVIG use has been shown to be lacking in some areas and promising in others. Conditions in which IVIG has been shown to have benefit include ITP, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy occurring in the context of rheumatic disease, as well as in SLE, idiopathic inflammatory myopathies and ANCA-associated vasculitides. This review looks at current IVIG use and is designed to be an aid for rheumatologists when considering the use of IVIG in clinical practice.

Palavras-Chave: IVIG, Kawasaki disease, intravenous immunoglobulin, lupus, myopathy, myositis, review, rheumatic disease, vasculitis

Imprenta: Rheumatology, v. 54, n. 3, p. 383-391, 2015

Identificador do objeto digital: 10.1093/rheumatology/keu429

Descritores: Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Inflammation ; Guillain-Barre Syndrome - Epidemiology

Data de publicação: 2015

INDICADORES

ACESSO